Analogic Corporation Launches the LIFEGARD II Family of Non-Invasive Patient Monitors at the ACC in Atlanta, March 11-14.

PEABODY, Mass. -- Analogic Corporation (NASDAQ: ALOG) today announced the official product launch of the LIFEGARD(R) II family of non-invasive patient monitors at ACC.06 (American College of Cardiology), March 11-14, 2006, in Atlanta, Georgia (Booth #3432).

The LIFEGARD II, the latest in a series of non-invasive patient monitors from Analogic, is the platform upon which the Company will expand its patient monitoring offerings. LIFEGARD II with ICG (Impedance CardioGraphy) uses Thoracic Electrical Bioimpedance (TEB) to measure continuous cardiac output, and is the only patient monitor that has ICG totally integrated with all other standard, non-invasive vital signs.

Non-invasive hemodynamic measurement is a valuable, established tool in managing cardiac patients, and the LIFEGARD II with ICG is the most comprehensive non-invasive cardiac output monitor available today.

Dan Webster, General Manager of Analogic's Life Care Systems Division, noted, "The LIFEGARD II family represents a significant expansion of our growing LIFEGARD family of patient monitors. The non-invasive, portable LIFEGARD II with ICG adds a new level of versatility to patient monitoring by allowing clinicians to more comprehensively monitor patient hemodynamics anywhere in the hospital or in non-acute environments such as freestanding clinics and physicians' offices. Clinicians can evaluate a patient in considerably less time and with no risk of infection, compared to conventional invasive monitoring modalities."

Analogic's LIFEGARD family of non-invasive patient monitors also includes LIFEGARD, a general-purpose monitor that measures ECG, heart rate, respiration, pulse oximetry, non-invasive blood pressure, and temperature; LIFEGARD ICG, a non-invasive hemodynamic status monitor; and the FETALGARD Lite(R) and FETALGARD Lite with NIBP, antepartum fetal monitors capable of monitoring twins. LIFEGARD II multiparameter monitors can also measure end-tidal CO2, in addition to ICG and the five standard vital sign parameters. Additional models with expanded capabilities which have already received U.S. Food & Drug Administration (FDA) clearance will be made available over the next 12 months. For more information, visit Booth #3432 at ACC in Atlanta, go to www.analogic.com/lifegard, or call 800-599-7769.

Analogic Corporation is a leading designer and manufacturer of advanced health and security systems and subsystems sold primarily to Original Equipment Manufacturers (OEMs). The Company is recognized worldwide for advancing the state of the art in Computed Tomography (CT), Digital Radiography (DR), Ultrasound, Magnetic Resonance Imaging (MRI), Patient Monitoring, and Embedded Multiprocessing.